As anti-PD-1 treatment is not approved for use in prostate cancer, we attempted to address this question in a cohort of 10 unresectable melanoma patients undergoing standard-of-care therapy with pembrolizumab. The gene discussed is PDCD1; the disease is prostate carcinoma.